A5069820090- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Acute Myocardial Infarction Research
- Cardiac Arrhythmias and Treatments
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Venous Thromboembolism Diagnosis and Management
- Cardiac pacing and defibrillation studies
- Lipoproteins and Cardiovascular Health
- Peripheral Artery Disease Management
- Cardiovascular Function and Risk Factors
- Infective Endocarditis Diagnosis and Management
- Cardiovascular and Diving-Related Complications
- Cerebrovascular and Carotid Artery Diseases
- Cardiac tumors and thrombi
- Cardiac and Coronary Surgery Techniques
- Cardiac Structural Anomalies and Repair
- Aortic aneurysm repair treatments
- Diabetes Treatment and Management
- Analytical Chemistry and Sensors
- Mesenchymal stem cell research
- Inflammatory mediators and NSAID effects
- Vascular Procedures and Complications
- Silicone and Siloxane Chemistry
Scripps Clinic
2016-2025
National Hospital for Neurology and Neurosurgery
2024
University College London
2024
University of Vermont
2011-2024
Scripps Green Hospital
2008-2023
Scripps Clinic Medical Group
2023
Scripps (United States)
2013-2022
Scripps Institution of Oceanography
2012-2022
Scripps Memorial Hospital
2021
New York Hospital Queens
2020
High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined.To evaluate the effect of high-dose compared with standard-dose in patients high on-treatment PCI.Randomized, double-blind, active-control trial (Gauging Responsiveness A VerifyNow assay-Impact on Thrombosis And Safety [GRAVITAS]) 2214 12 24 hours PCI drug-eluting stents at 83 centers North...
The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, St. Paul, Minnesota) was equivalent to warfarin preventing stroke fibrillation, but had a high rate of complications. In second randomized trial, PREVAIL (Evaluation WATCHMAN LAA Closure Device Fibrillation Versus Long Term Warfarin Therapy), complication low. cohort experienced an...
The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant PCI-related ischemic complications. Cangrelor a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects.In double-blind, placebo-controlled trial, we randomly assigned 11,145 patients who were undergoing either urgent or elective PCI receiving guideline-recommended to receive bolus infusion cangrelor loading dose 600...
AimsThe aim of this study was to determine whether platelet reactivity on clopidogrel therapy, as measured by a point-of-care function assay, is associated with thrombotic events after percutaneous coronary intervention (PCI) drug-eluting stents (DESs).
UAL ANTIPLATELET THERAPYwith aspirin and an oral P2Y 12 receptor inhibitor is the standard of care to prevent short-and long-term risk recurrent atherothrombotic events in high-risk settings, such as patients with acute coronary syndrome (ACS) those undergoing percutaneous intervention (PCI). 1-4However, ischemic benefit associated more intense platelet blockade these highrisk settings occurs at expense increased bleeding complications.Given that significantly among
Abstract Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are major importance, but a lack standardization in defining this population limits trial design, data interpretation, clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is collaboration among leading research organizations, regulatory authorities, physician-scientists from the United States, Asia, Europe focusing on...
Severe tricuspid regurgitation is a debilitating condition that associated with substantial morbidity and often poor quality of life. Decreasing may reduce symptoms improve clinical outcomes in patients this disease.We conducted prospective randomized trial percutaneous transcatheter edge-to-edge repair (TEER) for severe regurgitation. Patients symptomatic were enrolled at 65 centers the United States, Canada, Europe randomly assigned 1:1 ratio to receive either TEER or medical therapy...
In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce cardiovascular events compared with standard-dose in patients high on-treatment platelet reactivity (OTR) after percutaneous coronary intervention, defined as OTR ≥230 reaction units according to function test. The aim this analysis was examine relationship between outcomes over course trial.OTR measured at 12 24 hours 30±7 days...
Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use polymer-based drug-eluting stents, as compared polymer-free such limited.In an international, randomized, single-blind trial, we zotarolimus-eluting umirolimus-coated risk. After PCI, were therapy, followed by single The primary outcome was a safety...
ILUMIEN I is the largest prospective, non-randomized, observational study of percutaneous coronary intervention (PCI) procedural practice in patients undergoing intra-procedural pre- and post-PCI fractional flow reserve (FFR) optical coherence tomography (OCT). We report on impact OCT physician decision-making association with FFR values early clinical events.Optical documentary were performed 418 (with 467 stenoses) stable or unstable angina NSTEMI. Based pre-PCI OCT, procedure was altered...